Tandem Diabetes Care
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tandem Diabetes Care sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Tandem Diabetes Care: 13 sponsored US clinical trials, 1 recruiting.
Tandem Diabetes Care sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 1, with 2 trials.
Top-decile sponsor footprint
Tandem Diabetes Care ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes
NCT07325461
PS230005 Control-IQ 1.5 Post-Approval Study
NCT06717451
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
NCT06273124
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
NCT05785832
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes
NCT05683392
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
NCT05403502
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
NCT05422053
Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use
NCT05204134
Control-IQ Technology in Individuals With Type 2 Diabetes
NCT05111301
Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study
NCT05014789
Control-IQ Observational (CLIO) Post-Approval Study
NCT04503174
Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial
NCT03195140
Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study
NCT02877771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Tandem Diabetes Care pipeline
1 recruiting of 13 indexed (8% open); 11 completed (85%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Diabetes Mellitus, Type 1 (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tandem Diabetes Care: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Tandem Diabetes Care sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
Related
What to do with this Tandem Diabetes Care page
13 registered trials is a research-attention snapshot, not an endorsement of Tandem Diabetes Care or any single study.
- 1 of Tandem Diabetes Care's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 1 is the condition Tandem Diabetes Care studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 1 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tandem Diabetes Care pipeline card: 13 registered trials from official public datasets.Report a data error.